English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Breast cancer is the leading cancer affecting women worldwide. There are many factors associated with the emergence and development of this tumor type. There is large interindividual variability in both woman’s age at breast cancer diagnosis and the phenotypic expression existing at that moment, which makes the diagnosis challenging for any researcher. In the last decade, there was a better understanding of the molecular mechanisms involved in the progression of breast cancer and the central role of molecular changes in early detection of tumor. The challenge now is to learn how to use the individual tumor molecular characteristics of each patient and improve the current forms of detection and treatment, aiming at preventing the onset and the early diagnosis of the tumor. Currently, two methods are already widely used in United States of America to molecularly characterize breast tumors: MammaPrint and OncotypeDX. This paper aimed to discuss these two methods for breast cancer prognosis, in order to establish differences between them and their main application.

Utilização de plataforma gênica no prognóstico do câncer de mama